[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601785":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":179,"collaborators":20,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":183,"sex":189,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":20,"studyType":195,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},{"fullName":5,"class":6},"Vega Therapeutics, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multiple Doses of VGA039 after observational run-in","EXPERIMENTAL","Participants who meet eligibility criteria and complete a 24-week observational phase will receive VGA039 SC for approximately 49 weeks.",[13],"Drug: VGA039",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","VGA039","VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Clinical Trials- Vega Therapeutics","CONTACT","650-466-8041","medinfo@star-therapeutics.com",[28,42,52,61,70,83,89,99,114,124,134,147,157,168],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":20},"Arkansas Children's Hospital","RECRUITING","Little Rock","Arkansas","72202","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-92.28959,34.74648,{"lat":40,"lon":39},{"facility":43,"status":30,"city":44,"state":45,"zip":46,"country":34,"countryCode":35,"cosmosGeoPoint":47,"geoPoint":51,"contacts":20},"Luskin Orthopaedic Institute For Children","Los Angeles","California","90007",{"type":37,"coordinates":48},[49,50],-118.24368,34.05223,{"lat":50,"lon":49},{"facility":53,"status":30,"city":54,"state":45,"zip":55,"country":34,"countryCode":35,"cosmosGeoPoint":56,"geoPoint":60,"contacts":20},"UC Davis Medical Center","Sacramento","95817",{"type":37,"coordinates":57},[58,59],-121.4944,38.58157,{"lat":59,"lon":58},{"facility":62,"status":30,"city":63,"state":45,"zip":64,"country":34,"countryCode":35,"cosmosGeoPoint":65,"geoPoint":69,"contacts":20},"University of California San Francisco","San Francisco","94143",{"type":37,"coordinates":66},[67,68],-122.41942,37.77493,{"lat":68,"lon":67},{"facility":71,"status":30,"city":72,"state":73,"zip":74,"country":34,"countryCode":35,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Emory University Hospital","Atlanta","Georgia","30308",{"type":37,"coordinates":76},[77,78],-84.38798,33.749,{"lat":78,"lon":77},[81],{"name":71,"role":24,"phone":82,"phoneExt":20,"email":20},"(404) 686-0277",{"facility":84,"status":30,"city":72,"state":73,"zip":85,"country":34,"countryCode":35,"cosmosGeoPoint":86,"geoPoint":88,"contacts":20},"Children's Healthcare of Atlanta","30329",{"type":37,"coordinates":87},[77,78],{"lat":78,"lon":77},{"facility":90,"status":30,"city":91,"state":92,"zip":93,"country":34,"countryCode":35,"cosmosGeoPoint":94,"geoPoint":98,"contacts":20},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":37,"coordinates":95},[96,97],-93.26384,44.97997,{"lat":97,"lon":96},{"facility":100,"status":30,"city":101,"state":102,"zip":103,"country":34,"countryCode":35,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Science 37, Inc. (Virtual Clinical MetaSite)","Morrisville","North Carolina","27560",{"type":37,"coordinates":105},[106,107],-78.82556,35.82348,{"lat":107,"lon":106},[110],{"name":111,"role":24,"phone":112,"phoneExt":20,"email":113},"Science 37 Recruitment Team","1-855-737-3711","recruitment@science37.com",{"facility":115,"status":30,"city":116,"state":117,"zip":118,"country":34,"countryCode":35,"cosmosGeoPoint":119,"geoPoint":123,"contacts":20},"Hemophilia Center of Western PA","Pittsburgh","Pennsylvania","15213",{"type":37,"coordinates":120},[121,122],-79.99589,40.44062,{"lat":122,"lon":121},{"facility":125,"status":30,"city":126,"state":127,"zip":128,"country":34,"countryCode":35,"cosmosGeoPoint":129,"geoPoint":133,"contacts":20},"UT Southwestern Children's Hospital","Dallas","Texas","75235",{"type":37,"coordinates":130},[131,132],-96.80667,32.78306,{"lat":132,"lon":131},{"facility":135,"status":30,"city":136,"state":137,"zip":138,"country":34,"countryCode":35,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Washington Center for Bleeding Disorders","Seattle","Washington","98101",{"type":37,"coordinates":140},[141,142],-122.33207,47.60621,{"lat":142,"lon":141},[145],{"name":20,"role":24,"phone":20,"phoneExt":20,"email":146},"Research@WACBD.org",{"facility":148,"status":30,"city":149,"state":20,"zip":150,"country":73,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":20},"K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)","Tbilisi","0159","GE",{"type":37,"coordinates":153},[154,155],44.83412,41.69143,{"lat":155,"lon":154},{"facility":158,"status":30,"city":159,"state":20,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":167,"contacts":20},"Frankfurt University Hospital (Universitätsmedizin Frankfurt)","Frankfurt","60596","Germany","DE",{"type":37,"coordinates":164},[165,166],10.53333,49.68333,{"lat":166,"lon":165},{"facility":169,"status":30,"city":170,"state":20,"zip":171,"country":172,"countryCode":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":20},"Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist","Johannesburg","2194","South Africa","ZA",{"type":37,"coordinates":175},[176,177],28.04363,-26.20227,{"lat":177,"lon":176},{"type":180,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100601785","phase-3-study-to-evaluate-subcutaneous-sc-vga039-in-patients-with-von-willebrand-disease-vwd-100601785",false,"NCT07115004","Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)","A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)","VIVID-6","Key Inclusion Criteria\n\n* 12 to 75 years of age, inclusive\n* No clinically significant laboratory, ECG, or vital signs results\n* Documented diagnosis consistent with VWD of any type\n* Historical annualized bleeding rate (ABR; excluding menstrual bleeds and bleeds under the skin) of both untreated and treated bleeds ≥12 per year\n* Patients with VWD who are judged by the investigator to be suitable candidates for routine prophylaxis to reduce the frequency of bleeding episodes\n* Hemoglobin level ≥ 8 g\u002FdL and platelet count ≥ 100 x 109\u002FL at Screening\n\nKey Exclusion Criteria\n\n* Use of routine prophylaxis of VWF-containing concentrates defined as at least 1 VWF-containing concentrate infusion to prevent or reduce bleeding per week during the previous 6 months prior to screening\n* Planning to initiate routine prophylaxis with VWF-containing concentrates or any other hemostatic treatment during the study\n* Patients with pro-thrombotic disorders or abnormal findings on laboratory thrombophilia evaluation performed at screening or previously documented\n* History of arterial or venous thrombosis, including superficial thrombophlebitis, or embolism\n* Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, or metabolic dysfunction\n* Baseline FVIII activity \\> lower limit of normal (LLN)","ALL","12 Years","75 Years",{"count":193,"type":194},60,"ESTIMATED","INTERVENTIONAL",[197],"PHASE3","This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)",[200],"Von Willebrand Disease (VWD)",[202,203,187,204,205,17],"VWD","von Willebrand Disease","Vega Therapeutics","Star Therapeutics","2026-04-02",{"date":208,"type":209},"2026-04-03","ACTUAL",{"date":211,"type":209},"2025-10-15",{"date":213,"type":194},"2028-10",{"name":5,"class":6},14]